Genedx Holdings (WGS) reported $428M in revenue for fiscal 2025, +40.0% year on year. That ranks #2313 by revenue among 2853 SEC filers and #225 in Healthcare. It posted a net loss of −$21.0M for the same year. Revenue has grown 13.9% a year on average since 2019 ($196M then). The fiscal 2025 balance sheet shows $524M in total assets, $105M in cash and $48.2M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $428M | +40.0% | FY20252025-12-31 |
| Gross profitGrossProfit | $298M | +53.4% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$13.1M | +$10.1M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$21.0M | +$31.3M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $33.3M | +$61.8M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $19.0M | +246.3% | FY20252025-12-31 |
| Total assetsAssets | $524M | +24.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $308M | +25.7% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $105M | +23.2% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $48.2M | −7.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $102M | −$63.3M | Open → |
| Q2 20262026-06-30 | $114M | −$17.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Genedx Holdings Corp.
- Ticker
- WGS
- Exchange
- Nasdaq
- SIC classification
- Services-Health Services (8000)
- Fiscal year end
- 12-31
- CIK
- 0001818331
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 4, 2026Open filing →
- 10-KFeb 23, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AccurayARAY | $459M | −$1.6M |
| Tarsus PharmaceuticalsTARS | $451M | −$66.0M |
| ArtivionAORT | $441M | $9.8M |
| Genedx HoldingsWGS | $428M | −$21.0M |
| Mimedx GroupMDXG | $419M | $48.6M |
| InnovivaINVA | $411M | $271M |
| ArdelyxARDX | $407M | −$62.0M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Genedx Holdings — Key figures |url=https://companiesranked.com/en/company/genedx-holdings |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Genedx Holdings — Key figures. CompaniesRanked. https://companiesranked.com/en/company/genedx-holdingsBibTeX
@misc{companiesranked-en-company-genedx-holdings-2026,
author = {{CompaniesRanked}},
title = {{Genedx Holdings — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/genedx-holdings}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001818331-26-000015 · February 23, 2026
{{cite web |title=Genedx Holdings — Key figures — 10-K (0001818331-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1818331/000181833126000015/wgs-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-23}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.